Newsletters

  • All
  • AMR Action Fund
  • Can you help?
  • CARB-X
  • CDC
  • FDA
  • Government Action
  • Jobs
  • Meetings
  • PK & PK-PD
  • Push/Pull
  • R&D Insight
  • RFPs
  • Something Different
  • Summaries
  • Wellcome Trust
  • WHO
  • Wonkish
All
  • All
  • AMR Action Fund
  • Can you help?
  • CARB-X
  • CDC
  • FDA
  • Government Action
  • Jobs
  • Meetings
  • PK & PK-PD
  • Push/Pull
  • R&D Insight
  • RFPs
  • Something Different
  • Summaries
  • Wellcome Trust
  • WHO
  • Wonkish
R&D Insight

The threat of mirror bacteria: Ongoing conversations

Dear All, I wrote in a 12 Dec 2024 newsletter (“Mirror Bacteria: An AMR threat of unprecedented magnitude”) about the ...
Read More >
R&D Insight

Updated FDA Q&A on Antibacterials for Unmet Medical Need

Dear All, An updated version of FDA’s very helpful Q&A entitled “Antibacterial Therapies for Patients With an Unmet Medical Need ...
Read More >
Government ActionR&D Insight

UNGA 2024 action: Establishing an Independent Panel on Evidence for Action (IPEA)

Dear All, Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting ...
Read More >
Government ActionPush/Pull

Pull incentives in Europe: Next legislative steps

Dear All (Deeply wonkish alert! Settle in! Great stuff here!): For today, we have a deep dive into the ongoing ...
Read More >
R&D Insight

Extending STEDI to diagnostics: STRIDES

Dear All (and with thanks to Betsy Trainor for co-authoring), The idea of the STEDI values of an antibiotic (its ...
Read More >
Government ActionR&D Insight

MHRA compilation of regulatory guidance on phage products

Dear All, Attention phage developers — the UK MHRA have compiled all their regulatory guidance for phage into one convenient ...
Read More >
Government ActionSomething Different

D-Day: Churchill (1944) → WHO Pandemic Agreement and the Hamburg Statement (2025)

Dear All, D-Day and the momentous Normandy landings were 81 years ago today. In a marvelous new article on bbc.com (and ...
Read More >
R&D Insight

FDA Listening Sessions for CEOs, CMOs, or heads of R&D

Dear All, Pushing this one out as a direct quote from the online materials posted yesterday by FDA. Looks interesting! All ...
Read More >
R&D Insight

IDWeek 2025: Present your novel antimicrobial or diagnostic

Dear All, As in previous years  (27 Mar 2024 newsletter), IDWeek 2025 will feature pipeline-focused sessions for both antimicrobials and ...
Read More >
Something Different

Vaccine development: Polytheism vs. Monotheism

Dear All (and with a wonkish alert!), The idea of more (and better) vaccines to prevent (or even be part ...
Read More >
R&D InsightSomething Different

Impact of AMR on cancer therapy

Dear All (unapologetically wonkish … very important material!), Let’s set the scene today by considering two quotes: Prosaic: “The successful ...
Read More >
R&D Insight

Evolving the idea of DTR (Difficult-to-Treat Resistance) to include antibiotic access

Dear All (wonkish alert … lots of details here … take your time and absorb it all!), I’ve written several ...
Read More >
R&D Insight

Vivli’s 2025 AMR Surveillance Data Challenge

Dear All, We’ve previously discussed the availability of large surveillance datasets from the Vivli AMR Register. In particular, you should review Patricia ...
Read More >
R&D Insight

Manufacturing underpins access in LMICs: An update on cefiderocol

Dear All, No one is safe until we’re all safe! In the 7 April 2025 newsletter on antibiotic access (“UNSLAP: You ...
Read More >
Push/Pull

Most current global summary of Pull incentives

Dear All, I was recently asked about a ready summary of the current state of play of Pull incentives around ...
Read More >
Government Action

Sign-on letter encouraging AMR funding in the FY2026 US budget

Dear All, If you represent a US-based organization with an interest in AMR, there is an opportunity to sign a ...
Read More >
Push/PullSomething Different

UNSLAP: You reach for the antibiotic … and it’s not there!

Dear All (with thanks to Louise for co-authoring and with a wonkish alert … settle in for the ride!), Today’s ...
Read More >
R&D Insight

Antibacterial R&D is very hard! Two great pipeline reviews + an Industry-level view

Dear All (and with thanks to Stephan Harbarth for co-authoring this newsletter), A new review by Ursula Theuretzbacher and colleagues ...
Read More >
R&D Insight

WHO pipeline reviews: Antifungal agents and fungal diagnostics

Dear All, As you know, WHO have been steadfastly producing both priority pathogens lists (PPLs) and pipeline reviews. My current ...
Read More >
R&D Insight

Now live: HERA’s call for rapid point-of-care susceptibility devices

Dear All, I wrote in the 19 Feb 2025 newsletter about HERA’s 13m EUR call for rapid point-of-care susceptibility devices. The ...
Read More >
Scroll to Top